Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CSPI Expects Pfizer’s Centrum Claim Changes To Resonate Across Industry

This article was originally published in The Tan Sheet

Executive Summary

Pfizer will discontinue advertising claims for Centrum Ultra Women’s and Silver Women’s multivitamin supplements for “breast health” and Centrum Ultra Men’s and Silver Ultra Men’s for “colon health.”

You may also be interested in...



U.K. Centrum Ad Review Sets High Bar For Gender-Specific Claims

The U.K. Advertising Standards Agency says that while a television ad for Centrum multivitamins tailored to each gender did not make improper claims directly, the spot creates potential for consumers to believe it implies those claims.

U.K. Centrum Ad Review Sets High Bar For Gender-Specific Claims

The U.K. Advertising Standards Agency says that while a television ad for Centrum multivitamins tailored to each gender did not make improper claims directly, the spot creates potential for consumers to believe it implies those claims.

In Brief

Perrigo cleared for Zegerid OTC equivalent; Abbott Nutrition feels effects of international distribution model shift; Supreme Court passes on McNeil Tylenol preemption case; Calif. class action proceeds against POM Wonderful; multivitamins yield modest cancer-prevention benefits; study links PSE buys, meth labs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel